secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-08-12T20:27:08+00:00
Accession:  0001437749-26-027332
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Q2 net loss narrows to $1.6M; PMDA supports CardiAMP Japan filing
---------------------------------------------------------------------------

- Q2 2026 net loss $1.6M vs $2.0M year-ago; H1 loss $3.9M vs $4.8M.
- R&D expense down to $0.9M from $1.4M; cash $4.1M, runway into 2027.
- Raised ~$4.9M net proceeds from ATM facility in Q2.
- Japan PMDA supports Shonin submission for CardiAMP; filing targeted Q4 2026.
- FDA confirms CardiAMP HF II trial may support PMA; Helix DeNovo approval possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/0001437749-26-027332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/bcda20260812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer